Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

Ofatumumab is approved for the treatment of relapsing multiple sclerosis (RMS). Ongoing safety reporting is crucial to understand its long-term benefit-risk profile. Report the safety and tolerability of ofatumumab in RMS after extended treatment up to 3.5 years. Patients completing ASCLEPIOS I/II (...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis Jg. 28; H. 10; S. 1576
Hauptverfasser:	Hauser, Stephen L, Cross, Anne H, Winthrop, Kevin, Wiendl, Heinz, Nicholas, Jacqueline, Meuth, Sven G, Giacomini, Paul S, Saccà, Francesco, Mancione, Linda, Zielman, Ronald, Bagger, Morten, Das Gupta, Ayan, Häring, Dieter A, Jehl, Valentine, Kieseier, Bernd C, Pingili, Ratnakar, Stoneman, Dee, Su, Wendy, Willi, Roman, Kappos, Ludwig
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.09.2022
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects Humans Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy relapsing multiple sclerosis antibodies monoclonal Ofatumumab multiple sclerosis safety
ISSN:	1477-0970, 1477-0970
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!